Truist Securities analyst Scot Ciccarelli downgrades shares of Five Below to Hold from Buy, and cuts his price target. Continue reading
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. But Home Bancshares, Inc. (Conway, AR) (NYSE:HOMB) has fallen short of that second …
It has been about a month since the last earnings report for Lennar (LEN). Shares have added about 14.1% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Lennar due …
U.S. Bancorp’s USB second-quarter 2024 adjusted earnings per share (excluding the impact of notable items) of 98 cents beat the Zacks Consensus Estimate by 2%. However, the bottom line declined 12.5% from the prior-year quarter's level. Shares of USB have increased around 4.1% in …
Perdoceo Education Corporation PRDO inked a definitive agreement to acquire full ownership of the University of St. Augustine for Health Sciences, LLC (USAHS). The acquisition, likely to be valued at $142-$144 million, is set to be completed by December 2024. Founded in 1979, USAHS …
Northern Trust Corporation’s NTRS second-quarter 2024 earnings per share of $4.34 surpassed the Zacks Consensus Estimate of $1.75. The bottom line increased from $1.56 reported in the year-ago quarter. Shares of the company lost 4% in the early market trading despite achieving better-than-expected results …
Energy Transfer LP ET completed the previously announced acquisition of WTG Midstream Holdings LLC. The firm paid $2.28 billion in cash and nearly 50.8 million newly issued ET common units to complete the acquisition. This acquisition expanded Energy Transfer’s presence in the Midland Basin …
Johnson & Johnson’s JNJ second-quarter 2024 earnings came in at $2.82 per share, which beat the Zacks Consensus Estimate of $2.71. Earnings rose 10.2% from the year-ago period. Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported second-quarter …
Syros Pharmaceuticals, Inc. SYRS is developing its pipeline candidate, tamibarotene, an oral, selective, retinoic acid receptor alpha or RARα agonist as a frontline treatment of acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR-MDS). The FDA granted a Fast Track designation to tamibarotene for …
Key Insights Given the large stake in the stock by institutions, Astrana Health's stock price might be vulnerable to their trading decisions 50% of the business is held by the top 7 shareholders Insider ownership in Astrana Health is 12% A look at the …